Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ensysce Biosciences Inc
(OP:
ENSCW
)
0.0375
+0.0191 (+103.80%)
Streaming Delayed Price
Updated: 2:07 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ensysce Biosciences Inc
< Previous
1
2
Next >
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
November 07, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
October 08, 2024
Via
ACCESSWIRE
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
October 02, 2024
Via
ACCESSWIRE
Ensysce Biosciences Presenting at Upcoming Meetings
September 24, 2024
Via
ACCESSWIRE
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
September 13, 2024
Via
ACCESSWIRE
Ensysce Biosciences Provides Mid-Year 2024 Update
July 23, 2024
Via
ACCESSWIRE
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
July 09, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
June 25, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
June 06, 2024
Via
ACCESSWIRE
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
June 03, 2024
Via
ACCESSWIRE
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
May 20, 2024
Via
ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2024 Financial Results
May 13, 2024
Via
ACCESSWIRE
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
April 19, 2024
Via
ACCESSWIRE
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
April 09, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
February 15, 2024
Via
ACCESSWIRE
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study
November 16, 2023
Via
ACCESSWIRE
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
October 24, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Participate in Upcoming Industry Events
June 06, 2023
Via
ACCESSWIRE
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
January 25, 2024
Via
ACCESSWIRE
Ensysce Biosciences Issues 2024 Shareholder Letter
January 08, 2024
Via
ACCESSWIRE
Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
June 27, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
February 01, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study
January 25, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial
January 04, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection
December 19, 2022
Via
ACCESSWIRE
Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational
January 23, 2023
Via
ACCESSWIRE
Ensysce Biosciences Issues 2023 Shareholder Letter
January 11, 2023
Via
ACCESSWIRE
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering
December 07, 2022
Via
ACCESSWIRE
Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A
December 05, 2022
Via
ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2022 Financial Results
November 14, 2022
Via
ACCESSWIRE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
